Uchida Takayuki, Nasu Motomi, Hashimoto Takashi, Tsurumaru Masahiko, Kajiyama Yoshiaki
Juntendo Iji Zasshi. 2022 Oct 4;68(5):513-520. doi: 10.14789/jmj.JMJ22-0008-OA. eCollection 2022.
Some previous studies reported that the levels of a low-density lipoprotein receptor relative with 11 ligand-binding repeats (LR11) was a prognostic marker in some malignant tumors; however, whether LR11 is related to survival in patients with esophageal cancer remains unclear.
In this study, we measured LR11 in the preoperative serum of 46 patients of esophageal cancer who undergoing surgery using a sandwich enzyme-linked immunosorbent assay (ELISA) method with anti-LR11 monoclonal antibodies. We investigated the correlation between the level of LR11 and survival of patients with esophageal cancer. Clinicopathological data were retrospectively retrieved from our institution's database.
The patients were divided into two groups (low LR11 and high LR11) based on the level of LR11. There was no statistical difference in clinicopathological factors between these two groups. The low LR11 group had a significantly longer overall survival than the high LR11 group.
LR11 can be measured with a relatively simple ELISA and is potentially a new prognostic marker for esophageal cancer.
一些先前的研究报道,具有11个配体结合重复序列的低密度脂蛋白受体(LR11)水平在某些恶性肿瘤中是一种预后标志物;然而,LR11是否与食管癌患者的生存相关仍不清楚。
在本研究中,我们使用抗LR11单克隆抗体的夹心酶联免疫吸附测定(ELISA)方法,测量了46例接受手术的食管癌患者术前血清中的LR11。我们研究了LR11水平与食管癌患者生存之间的相关性。临床病理数据是从我们机构的数据库中回顾性获取的。
根据LR11水平将患者分为两组(低LR11组和高LR11组)。这两组之间的临床病理因素无统计学差异。低LR11组的总生存期明显长于高LR11组。
LR11可以通过相对简单的ELISA进行测量,并且可能是食管癌的一种新的预后标志物。